Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Holding CRNX?
Track your performance easily
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.75 - $60.93
Previous Close$60.69
Volume573.32K
Average Volume (3M)662.85K
Market Cap
$5.39B
Enterprise Value$4.58B
Total Cash (Recent Filing)$862.95M
Total Debt (Recent Filing)$53.32M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 12, 2024EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding80,035,610
10 Day Avg. Volume535,897
30 Day Avg. Volume662,846
Standard Deviation0.16
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.85
Price to Sales (P/S)3456.27
Price to Cash Flow (P/CF)-26.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.30K
Enterprise Value/Gross Profit1.14K
Enterprise Value/Ebitda-17.36
Forecast
1Y Price Target
$81.25Price Target Upside33.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Crinetics Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe results demonstrated an impressive degree of efficacy across the board, with paltusotine hitting all primary and secondary endpoints.
Market PotentialThe announced topline results from the PATHFNDR-2 study in undertreated patients solidifies paltusotine's regulatory positioning and expands the commercial potential beyond switching patients alone.
Regulatory ProgressAn NDA submission for paltusotine in acromegaly guided for H2 will mark Crinetics’ first regulatory submission to bring a product across the finish line for approval.
Bears Say
Clinical TrialsAll five patients on once-daily 80 atumelnant for 10 days experienced biochemical evidence of adrenal insufficiency by Day 2 of treatment.
Drug Side EffectsAtumelnant is working and normalizing urinary free cortisol but also causing adrenal insufficiency that requires GC replacement.
Regulatory And Approval RiskRisks include clinical trial results might not meet expectations, regulatory and approval risk, funding risk, commercial adoption, the effects of COVID 19, and possible dilution.
---
Ownership Overview
7.41% Insiders
27.35% Mutual Funds
6.99% Other Institutional Investors
44.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $25.75 and its highest was $60.93 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.859 by -$0.081.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.91.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 90,035,610 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.859. Following the earnings report the stock price went down -6.11%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 274M.
---
Crinetics Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.25 (33.88% Upside)
$81.25 (33.88% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.32%
12-Months-Change
Fundamentals
Return on Equity
-47.66%
Trailing 12-Months
Asset Growth
219.02%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q2 2024
0:00 / 0:00
---
CRNX Stock 12 Month Forecast
Average Price Target
$81.25
▲(33.88% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Ultragenyx Pharmaceutical
―
Fate Therapeutics
―
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+95.73%
reiterated a buy rating 3 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +95.73% per trade.
---